Page 2,990«..1020..2,9892,9902,9912,992..3,0003,010..»

Cocaine-Related Heart Damage May Be 'Silent'

Posted: June 26, 2011 at 4:06 pm

(HealthDay News) -- Heart damage caused by heavy cocaine use can occur without producing any symptoms, according to a new study.

Researchers assessed the heart health of 30 long-term cocaine users, average age 37, who entered a drug rehabilitation program 48 hours after they last used cocaine. They had been using cocaine for an average of 12 years and consumed about 5.5 grams of cocaine per day.

Snorting was the most common way of using cocaine, but 10 said they injected intravenously and two said they smoked it (crack cocaine).

More than half of the those addicted to cocaine also used other substances -- such as heroin and alcohol -- and one in five was infected with either hepatitis C or HIV.

Heart function was normal in all the daily cocaine users, but 12 had localized abnormalities, 83 percent had structural damage, and 47 percent had swelling (edema) in the lower left ventricle. Edema was associated with greater cocaine consumption. Read more...

Cardiofy Heart Care Supplement

Posted in Integrative Medicine | Comments Off on Cocaine-Related Heart Damage May Be 'Silent'

Kurt May to Join International Stem Cell Corporation as Senior Vice President

Posted: June 26, 2011 at 4:05 pm


Andrey Semechkin, Ph.D., CEO of International Stem Cell Corporation (OTCBB:ISCOE) ("ISCO") announced today that Kurt May, a highly experienced senior business executive and biotechnology entrepreneur, is concluding his service as a faculty member at the University of San Diego's School of Business Administration and is joining ISCO as a Senior Vice President.


Mr. May's duties will include mergers and acquisitions and development of new international collaborations, and he will work directly with Dr. Semechkin in implementing the Company's business model of combining cutting-edge scientific research and building multiple revenue streams to support that research.


Prior to joining ISCO, Mr. May was a senior executive with GTE Corporation, a Fortune 50 company, where he enjoyed 23 years of progressive management experience. Mr. May then went on to serve as Executive Vice President and Chief Operating Officer with PriceSmart Inc. Since 2001 Mr. May has founded and led a privately owned biotech company, Psynomics Inc., as CEO. Psynomics Inc. is a spin out of the University of California San Diego, where Mr. May served as a faculty member and Assistant Dean of the Rady School of Management from 2005 until 2009.


"Mr. May strengthens an accomplished management team at ISCO, and I am delighted that we attracted a professional of his caliber to our Company," said ISCO'S CEO, Dr. Semechkin.


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.



To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


Forward-looking Statements
Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110621005505r1&sid=14230&distro=ftp
International Stem Cell Corporation
Andrey Semechkin, PhD
CEO & President
760-940-6383
aes@intlstemcell.com

or:
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Kurt May to Join International Stem Cell Corporation as Senior Vice President

Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale

Posted: June 26, 2011 at 2:38 pm

(Part 3 of 8) Don Cleveland, Ph.D. spoke at the "Spotlight on Disease Team Awards: ALS," an educational event presented at the CIRM Governing Board meeting on June 23, 2010. Goldstein is a co-principle investigator of the CIRM ALS Disease Team and member of The Ludwig Institute

Go here to see the original:
Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale

Posted in Stem Cell Therapy | Comments Off on Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale

Lou Gehrig’s Disease (ALS): UCSD Team’s Stem Cell Therapy Approach

Posted: June 25, 2011 at 4:16 pm

(Part 2 of 8) Larry Goldstein, Ph.D. spoke at the "Spotlight on Disease Team Awards: ALS," an educational event presented at the CIRM Governing Board meeting on June 23, 2010

Link:
Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Approach

Posted in Cell Therapy | Comments Off on Lou Gehrig’s Disease (ALS): UCSD Team’s Stem Cell Therapy Approach

Stem cells chi kung practice 2010#1) Theory

Posted: June 25, 2011 at 2:33 am

Stem cells chi kung practice by Master Mantak Chia, world tour work shop at Frankfurt, Germany 2010. more information please contact;universaltao@universal-tao.com,info@tao-garden.com visit our website;www.universal-tao.com http://www.tao-garden.com join our social network; http://www.taogathering.ning.com

Continued here:
Stem cells chi kung practice 2010#1) Theory

Posted in Stem Cell Videos | Comments Off on Stem cells chi kung practice 2010#1) Theory

Fibrocell Stem-Cell Wrinkle Smoother Wins FDA Clearance

Posted: June 23, 2011 at 2:03 pm

June 22 (Bloomberg) -- Fibrocell Science Inc. won US approval for an injectible wrinkle treatment that uses a patient's own stem cells to restore elasticity to the skin. The Food and Drug Administration cleared azficel-T, the company said today in a statement.

See the rest here:
Fibrocell Stem-Cell Wrinkle Smoother Wins FDA Clearance

Posted in Stem Cell Videos | Comments Off on Fibrocell Stem-Cell Wrinkle Smoother Wins FDA Clearance

TRANSPLANT VIEWS: Stem cell therapy used for diabetic patients

Posted: June 23, 2011 at 11:27 am

Stem cell therapy used for diabetic patients: "CHENNAI: Doctors in the city claim to have achieved a major breakthrough in saving the legs of several diabetic patients from amputation using stem cell therapy . ...

CHENNAI: Doctors in the city claim to have achieved a major breakthrough in saving the legs of several diabetic patients from amputation using stem cell therapy. Vascular surgeons from Vijaya Hospital, Vadapalani, along with stem cell experts from Nichi-In Centre for Regenerative Medicine (NCRM), claimed to have cured leg ulcers using stem cells from the patient’s own bone marrow.

The patients, who were initially advised to have their legs amputated to avoid spreading of infection and septicemia, were walking on their own feet, the doctors claimed.
Dr S R Subramanniyan, Chief Vascular Surgeon, Vijaya Hospital, told Express that the cases of Vimala (67), a long time diabetic, and Veeragovindaraj, in his late fifties, posed a challenge before them.

While Veeragovindaraj already had one leg amputated and was advised to cut off the other one to prevent spread of infection, Vimala had one limb severely infected and ready to be cut off. “In Veeragovindaraj’s case, we could not even do a bypass as his blood vessels did not have adequate length. We were fighting to save his only limb of which, he had already lost the heel and the forefoot. For him, turning on bed itself was arduous,” said Dr Subramanniyan.

Vimala’s case was also critical as the infection had spread up to her knees, he added. In both cases, the stem cells were drawn from their bone marrow and isolated before being auto transplanted into the ischemic area. In a couple of weeks, there were signs of rejuvenation. “While injecting, we kept tabs on the quantity of stem cells injected for standardisation. We even checked for infection indicators,” Dr Subramanniyan added. Gradually, the condition of the blood vessels improved and blood supply to the lower limbs also became better.

“Veeragovindaraj is now in Bangalore while Vimala is able to walk about in her house. These cases give hope to millions of diabetics in India,” Dr Samuel J K Abraham, Director, NCRM, told Express over phone from Yamanashi, Japan. This study on patients with severe uncontrolled diabetes, published in Cytotherapy, the official journal for the International Society for Cellular Therapy (ISCT), is claimed to possibly be the first such case in India.

Continue reading here:
TRANSPLANT VIEWS: Stem cell therapy used for diabetic patients

Posted in Diabetes, Stem Cell Therapy | Comments Off on TRANSPLANT VIEWS: Stem cell therapy used for diabetic patients

edivet America Dog Arthritis Stem Cell Therapy Stem Cell Therapy for Equine 1

Posted: June 23, 2011 at 4:38 am

Here is the original post:
edivet America Dog Arthritis Stem Cell Therapy Stem Cell Therapy for Equine 1

Posted in Cell Therapy | Comments Off on edivet America Dog Arthritis Stem Cell Therapy Stem Cell Therapy for Equine 1

Stem Cell Therapy for Multiple Sclerosis (MS patient)

Posted: June 23, 2011 at 3:23 am

http://www.cellmedicine.com

The rest is here:
Stem Cell Therapy for Multiple Sclerosis (MS patient)

Posted in Stem Cell Therapy | Comments Off on Stem Cell Therapy for Multiple Sclerosis (MS patient)

Heart Disease And Cardiac Failure: The Role Of Stem Cells …

Posted: June 23, 2011 at 3:23 am

Stem cell therapy for cardiac failure has astounded the medical profession and resulted in the immediate implementation of clinical trials to fast-track regulation and implementation. The available treatment protocol for ..

Heart Disease And Cardiac Failure: The Role Of Stem Cells

Stem cell therapy for cardiac failure has astounded the medical profession and resulted in the immediate implementation of clinical trials to fast-track regulation and implementation. The available treatment protocol for cardiac failure has been used successfully since 2007 and is the same procedure that is to be followed in future FDA-approved clinical trials. Patients with extremely poor ejection fractions have responded well enough to return to a normal lifestyle with minimal medication needs.

Stem cell therapy and cardiac failure

Stem cell therapy is the latest tool in regenerative cardiac medical therapy. Its potential for use in cardiovascular disease has only recently been recognized in clinical trials. A randomized study was conducted in 20 patients to deploy stem cells as an adjuvant to conventional revascularization therapy in patients with congestive heart failure. 1

Injections of adult stem cells into damaged heart tissue significantly improved heart function in patients with severe congestive heart failure, according to results of the first prospective randomized trial of the experimental therapy. 4

The results were astounding in that this study proved that in the early stages of recovery the stem cell transplant group fared the same as the surgical group, but at one month post-treatment, the gap widened to show that the stem cell treated group started doing better and the surgical group stagnated. This carried through for the rest of the study period and by six months the stem cell treated group had improved an average of 46% as compared to only 35% in the surgically treated group.1 The head researcher for this study stated their findings provide the first convincing evidence that transplantation of adult stem cells that promote growth of blood vessels and heart muscle can be a viable treatment for congestive heart failure.4

It is now becoming widely accepted that stem cells can repair heart tissue and now the structure of clinical trials seems to be focused on how many and what type of cells to use and not whether this works or not. During the writing of this article the author noted 6 FDA-approved clinical trials currently recruiting patients. 2

In 2008, Mayo Clinic investigators have demonstrated that stem cells can be used to regenerate heart tissue to treat dilated cardiomyopathy, one of the causes of cardiac failure. Interesting to note here is that the responses also seemed to start after one month as in the first study mentioned above.3

We see that by using the correct stem cells augmented by RegAmp in a minimally invasive procedure we achieve the same results, which according to our track record, is, on average a 40% improvement over baseline after three months. These are the best results available today and are borne out by their similarity to results that have been attained in animal and human studies in FDA-approved clinical trials. We have not experienced any adverse events in any of our patients during this safe and effective procedure, which can be performed at any one of the Regenecell clinics worldwide.

Additional informaton can be found at http://www.regenecell.com

References:
1. Patel A N et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study. J Thor & Card Surgery. Vol 130, Issue 6, Pages 1631-1638 (December 2005).
2. Clinicaltrials.gov
3. Physorg.com
4. mirm.pitt.edu/news

Dr Jeff Peimer MBChB (UCT) is a medical doctor with extensive experience in regenerative medicine, mental health and emergency medicine. He is the medical director of Regenecell, a company specialising in stem cell treatments. Jeff is consulted extensively by patients and their families who need help evaluating stem cell treatment. His main area of interest is the treatment of severe disease and injury by using umbilical cord stem cells.
He lives in Cape Town with his wife and two sons.

Visit the Regenecell website for more on stem cell therapy or Jeff’s Facebook page here

Original post:
Heart Disease And Cardiac Failure: The Role Of Stem Cells ...

Posted in Stem Cell Therapy | Comments Off on Heart Disease And Cardiac Failure: The Role Of Stem Cells …

Page 2,990«..1020..2,9892,9902,9912,992..3,0003,010..»